We evaluated the prognostic significance of PD-L1 expression in metastatic EGFR-mutated NSCLC patients, categorizing them into PD-L1 < 50% and PD-L1 ≥ 50% groups. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.